All In Biotech

Drug Trial Radar · NCT05679401

A Study With Imlifidase in Anti-GBM Disease

A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease)

Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

50

Actual

Start

Dec 22, 2022

Primary completion

Jun 23, 2025

Study completion Feb 2, 2026

Sponsor

Lead sponsor
Hansa Biopharma ABIndustry
Sponsor type
Industry
First posted
Jan 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.

Conditions

  • Anti-Glomerular Basement Membrane Disease
  • Anti-Glomerular Basement Membrane Antibody Disease
  • Goodpasture Syndrome
  • Good Pasture Syndrome

Interventions

  • ImlifidaseDrug

    Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.

  • Plasma exchange (PLEX)Procedure

    PLEX removes the patient's pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.

  • Cyclophosphamide (CYC)Drug

    Cyclophosphamide's main mechanism of action (i.e. crosslinking of strands of DNA and RNA) results in inhibition of protein synthesis. Hence treatment prevents formation of new anti-GBM antibodies.

  • GlucocorticoidsDrug

    Glucocorticoids inhibit the inflammation process.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Renal function as evaluated by estimated glomerular filtration rate (eGFR) at 6 monthsTime frame: At 6 months after randomisation

Locations

48 sites in 13 countries. Site status is shown where the registry gives one.

  • UCLA Medical Center Plaza

    Los Angeles, California

  • John Hopkins Medical Institution

    Baltimore, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Minnesota Health Clinical Research Unit

    Minneapolis, Minnesota

  • UNC Kidney Center/Division of Nephrology & Hypertension

    Chapel Hill, North Carolina

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Medical University of Vienna, Dept of Medicine III, Division of Nephrology and dialysis

    Vienna, Austria

  • Med Uni Graz / LKH-UNIV Klinikum Graz, Klinische Abteilung fuer Nephrologie

    Graz, Stiermark, Austria

  • Medical University Innsbruck, Dept of Internal Medicine IV (Nephrology and Hypertension)

    Innsbruck, Tyrol, Austria

  • UZ Leuven

    Leuven, Belgium

  • Všeobecná fakultní nemocnice v Praze

    Prague, Prague, Czechia

  • Rigshospitalet, Department of Nephrology

    Copenhagen, Denmark

  • Aarhus University Hospital, Renal Medicine and Clinical Medicine

    Aarhus N, Central Jutland, Denmark

  • Odense University Hospital, Medical Nephrology, Department Y

    Odense, Region Syddanmark, Denmark

  • CHU Grenoble Alpes - Michallon Hospital, Nephrology, Hemodialysis, Apheresis and Kidney Transplantation

    Grenoble, Auvergne-Rhône-Alpes, France

  • University Hospital of Marseille, Nephrology - Renal transplantation service

    Marseille, Bouches-du-Rhône, France

  • Nouvel Hôpital Civil (University Hospital of Strasbourg)

    Strasbourg, Grand Est, France

  • CHU Lille. Nephrology, dialysis transplantation

    Lille, Haus-de-France, France

  • Tenon Hospital, Renal intensive care unit

    Paris, Île-de-France Region, France

  • CHU Bordeaux, Hôpital Pellegrin, Service nephrologie, transplantation, dialyse, aphereses

    Bordeaux, New Aquitaine, France

  • CHU de Rouen, Department of Nephrology,Transplantation, and Hemodialysis

    Bois-Guillaume, Normandy, France

  • Hôpital Rangueil, CHU de Toulouse, Department of Nephrology and Organ transplantation

    Toulouse, Occitanie, France

  • CHU de Nantes, Hôtel-Dieu, Le service de néphrologie et immunologie clinique

    Nantes, Pays de la Loire Region, France

  • Charité Department of Nephrology and Intensive Care

    Berlin, Germany

  • Universitaetsklinikum Erlangen - Medizinische Klinik 4

    Erlangen, Germany

  • University Hospital Hamburg-Eppendorf, III Department of Medicine and Nephrology

    Hamburg, Germany

  • LMU Klinikum, Medical Clinic IV / Department of Nephrology

    Munich, Bavaria, Germany

  • Uniklinik RWTH Aachen

    Aachen, North Rhine-Westphalia, Germany

  • Uniklinik Koeln-Klinik II fuer Innere Medizin

    Cologne, North Rhine-Westphalia, Germany

  • Carl-Gustav-Carus University Hospital, Medizinische Klinik III, Nephrologie

    Dresden, Saxony, Germany

  • Department of Renal Medicine, Cork University Hospital

    Cork, Ireland

  • IRCCS S. Orsola - Malpighi University Hospital - Nephrology, Dialysis and Transplantation Unit (pav 15)

    Bologna, Italy

  • ASST degli Spedali Civili di Brescia - SC Nefrologia

    Brescia, Italy

  • IRCCS Policlinico San Martino University Hospital, Department of Internal Medicine, Division of Nephrology

    Genova, Genova-Liguria, Italy

  • University Medical Center Groningen, Division of Nephrology

    Groningen, Netherlands

  • Radboudumc

    Nijmegen, Netherlands

  • Leiden University Medical Center, Department of Nephrology

    Leiden, South Holland, Netherlands

  • University Hospital Vall d'Hebron

    Barcelona, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Karolinska University Hospital

    Huddinge, Sweden

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.